“…Ten studies (8 observational studies, 2 RCTs) examined changes in depression symptoms following Natalizumab treatment (Iaffaldano et al, 2012;Kunkel et al, 2015;Lang et al, 2012;Nagesh et al, 2015;Penner et al, 2015;Ratchford et al, 2014;Rorsman et al, 2017;Rudick et al, 2006;Sater et al, 2016;Svenningsson et al, 2013); only 5 provided the information needed for meta-analysis. The meta-analysis of these studies (Kunkel et al, 2015;Lang et al, 2012;Ratchford et al, 2014;Rorsman et al, 2017;Sater et al, 2016), found that depression symptoms improved (Fig. 4C, SMD: 0.31 [−0.06; 0.68]), although this was not statistically significant.…”